Pediatric IBD Patients Treated With Infliximab and Proactive Drug Monitoring Benefit From Early Concomitant Immunomodulatory Therapy: A Retrospective Analysis of a 10-Year Real-Life Cohort.
Hannes HoelzLena BragagnaAnna LitwinSibylle KoletzkoThu Giang Le ThiTobias SchwerdPublished in: Inflammatory bowel diseases (2023)
Early IMM combo-therapy in proactively monitored patients with pIBD significantly prolonged the median LOR free interval compared with late/short or no IMM treatment.